藍鳥生物公司 (BLUE)

0.9478 -0.0722 (-7.08%) 收市：04:00PM EDT

藍鳥生物公司

455 Grand Union Boulevard
Somerville, MA 02145
United States
339 499 9300
https://www.bluebirdbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 323

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Andrew Obenshain	President, CEO & Director	1.04M	無	1974
Mr. Thomas J. Klima	Chief Commercial Officer & COO	654.97k	無	1972
Mr. Richard A. Colvin M.D., Ph.D.	Chief Medical Officer	696.24k	無	1966
Mr. Oliver James Sterling III	CFO & Principal Accounting Officer	無	無	無
Mr. Joseph D. Vittiglio Esq., J.D.	Chief Legal & Business Officer and Secretary	無	無	1972
Jess Rowlands	Head of Corporate Communications	無	無	無
Ms. Andrea Walton	Chief People Officer	無	無	無
Mr. Kasra Kasraian	Senior Vice President of Technical Development & Operations	無	無	無
Mr. Scott Shoemaker	Senior Vice President of Quality	無	無	無
Ms. Sarah Alspach	Senior Vice President of External Affairs	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

公司管治

截至 2024年6月1日 止，藍鳥生物公司 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：9；董事會：3；股東權利：5；現金賠償：4。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。